TP53 gene mutations are prevalent in breast cancer, occurring in 20–30% of cases, and have been associated with more aggressive subtypes of the disease, as evidenced by studies (Shahbandi, Nguyen & Jackson, 2020). This evidence concerns the gene TP53 and breast cancer.